Toripalimab Biosimilar – Research Grade
ichorbio’s Toripalimab Biosimilar – Research Grade is manufactured in a cGMP compliant facility. This Toripalimab biosimilar is for Research Use Only (RUO) and not for therapeutic use.
ichorbio’s Toripalimab biosimilar is available in the following sizes:
5mg, 10mg, 20mg, 50mg
ichorbio regularly manufactures bulk multi-gram amounts of our Toripalimab biosimilar – please contact us for pricing.
Programmed cell death protein 1, Pdcd1, CD279
Detects human PD-1. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Toripalimab.
This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Toripalimab biosimilar is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It is an IgG4 kappa immunoglobulin with an approximate molecular weight of 149 kDa.
1.0 – 5.0 mg/ml
Sterile, preservative-free, clear to milky white colorless to slightly yellow solution, containing L-histidine , polysorbate 80 and sucrose. pH set to 5.5. BSA and Azide free.
>95% by SDS-PAGE and HPLC
≤ 0.75 EU/mg as determined by the LAL method
Toripalimab Biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Each investigator should determine their own optimal working dilution for specific applications.
ichorbio’s Toripalimab biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.